Drug intelligence / Profile preview

BR1016C

Development stage: Unknown
Lead developer: Boryung
Administration: Oral

Overview

BR1016C is an investigational drug formulation being evaluated in clinical trials to compare its pharmacokinetics and safety profile with BR1016D in healthy adults. It is administered orally as a tablet. Further details regarding its mechanism of action, therapeutic class, active ingredient, or primary indication are not publicly available.

Beyond the preview

Go deeper on BR1016C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1016C.

Explore the full profile